NDRA (ENDRA Life Sciences) חוב לטווח קצר להון

ENDRA Life Sciences (NDRA) is just beginning large-scale shipments of its fatty liver analysis systems, which is causing current distribution costs to temporarily weigh on profitability. The business relies on the sale of unique TAEUS devices, which replace expensive MRI with affordable ultrasound. This chart of the market value demonstrates that the separate_debt_short_eq metric stands at 0.01. The team consists of leading engineers attracted by innovative R&D and a flexible work format.

Investors are evaluating the operating model of ENDRA Life Sciences (NDRA) through the ratio of short-term liabilities to equity, which reveals a hidden degradation of liquidity and the risk of asset impairment as borrowings increase. By analyzing the current level of short-term capital pressure, one can understand how the stagnation of the US base growth due to FDA delays is forcing the company to increase urgent debt to maintain its ultrasound ecosystem.